Joachim Aerts, MD PhD
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (NCT05927142) | Joachim Aerts, MD PhD | 2024-01-09 |
| MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) (NCT05650918) | Joachim Aerts, MD PhD | 2021-08-30 |
| The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC (NCT05902260) | Joachim Aerts, MD PhD | 2021-07-06 |
Track Joachim Aerts, MD PhD automatically
Every clearance here is in the API, with alerts when new ones post.